Cardiff Oncology Inc (NASDAQ:CRDF) price on Thursday, February 27, fall -8.97% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $4.06.
A look at the stock’s price movement, the close in the last trading session was $4.46. Turning to its 52-week performance, $6.42 and $1.72 were the 52-week high and 52-week low respectively. Overall, CRDF moved 18.71% over the past month.
Cardiff Oncology Inc’s market cap currently stands at around $270.06 million, with investors looking forward to this quarter’s earnings report slated for in March.
The average forecast suggests down to a -43.41% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 462k, representing a -32.36% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CRDF is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend CRDF as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
CRDF’s current price about -7.01% and -1.23% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 47.06, while 7-day volatility ratio is 8.90% and 9.13% in the 30-day chart. Further, Cardiff Oncology Inc (CRDF) has a beta value of 1.72, and an average true range (ATR) of 0.38.
If we refocus on Cardiff Oncology Inc (NASDAQ:CRDF), historical trading data shows that trading volumes averaged 2.14 million over the past 3 months. The company’s latest data on shares outstanding shows there are 66.52 million shares.
The 10.13% of Cardiff Oncology Inc’s shares are in the hands of company insiders while institutional holders own 34.49% of the company’s shares. Current price change has pushed the stock -6.45% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CRDF stock continues to rise going into the next quarter.
